Administration Agreements in the Biotechnology Industry
8 Contracts & Agreements
- ALBIREO PHARMA, INC. (3 contracts)
- Athenex, Inc. (1)
- BIOXYTRAN, INC (1)
- FIBROGEN INC (1)
- MANNKIND CORP (2)
- Approval of International Patent WO2022/099061 - Polysaccharides for IV Administration that Treat SARS-CoV-2 Infections, dated May 12, 2022 (BIOXYTRAN, INC, Filed With SEC on June 10, 2022)
- Intercreditor Agreement dated as of August 4, 2020, by and among Oaktree Fund Administration, LLC, as administrative agent, and Sagard Healthcare Royalty Partners, LP, and as... (Athenex, Inc., Filed With SEC on November 5, 2020)
- State-Owned Construction Land Use Right Granting Contract Promulgated by Ministry of Land and Resources of the Peoples Republic of China State Administration for Industry and... (FIBROGEN INC, Filed With SEC on May 9, 2017)
- our ability to secure approval by the U.S. Food and Drug Administration, or FDA, for our product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or... (ALBIREO PHARMA, INC., Filed With SEC on December 14, 2009)
- our ability to secure approval by the U.S. Food and Drug Administration, or FDA, for our product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or... (ALBIREO PHARMA, INC., Filed With SEC on December 14, 2009)
- our ability to secure approval by the U.S. Food and Drug Administration, or FDA, for our product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or... (ALBIREO PHARMA, INC., Filed With SEC on December 14, 2009)
- the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental... (MANNKIND CORP, Filed With SEC on February 27, 2009)
- the risk of severe hypoglycemia, which is abnormally low levels of blood glucose that result from excessive insulin administration. Hypoglycemia can result in loss of mental... (MANNKIND CORP, Filed With SEC on March 14, 2008)
